Prof Fabrice André - Institut Gustave Roussy, Paris, France
Prof Fabrice André presents data at the ESMO 2018 congress in Munich from a phase III combination therapy trial including a targeted PI3K inhibitor to treat men and post-menopausal women with advanced breast cancer.
For more on these findings, watch his interview with ecancer here.